

Transforming Growth Factor – B1 and Pre-Eclampsia: Perspectives for Novel Therapeutic Modalities

Parveen Jahan¹, Goske Deepthi², Kamakshi Chaithri Ponnaluri² and Komaravalli Prasanna Latha²

¹Department of Zoology, MANUU, Hyderabad-32, Telangana State, India

²Department of Genetics, Osmania University, Hyderabad-07, Telangana State, India

*Corresponding author: Parveen Jahan, Department of Zoology, MANUU, Hyderabad-32, Telangana State, India, Tel: 9885186923; E-mail: dr.pjahan@gmail.com

Received date: February 17, 2016, Accepted date: March 7, 2016, Published date: March 10, 2016

Copyright: ©2016 Jahan P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Breakdown in the immunoregulatory mechanism as well as dysregulated angiogenesis are critical contributors to the obstetric disorder, Pre-eclampsia [PE]. The pleiotropic cytokine, Transforming Growth Factor- β 1 [TGF- β 1], with its immunosuppressive and angiogenic functions appears to be a promising candidate for prospective therapies in PE, as gleaned from a survey of candidate gene association and biochemical investigations. The current article endows with a background and gives inkling for the plausible therapeutic strategies for PE employing TGF- β 1, given the veracity that proper curative procedures are not yet existent for this disorder.

Keywords: Pre-eclampsia; Transforming Growth Factor- β 1; Gene Polymorphisms; Therapeutics

Introduction

Pre-eclampsia [PE] is a pregnancy specific vascular disorder resulting in considerable maternal and perinatal morbidity and mortality. Clinically and symptomatically PE is characterized by hypertension and proteinuria after the 20th week of gestation. The incidence of PE in the United States and European countries ranges from 2-5% and the incidence are much higher in the developing nations, 8-10% of all pregnancies in India [1]. PE is estimated to be the leading cause of maternal mortality in Latin America [2-4].

Descriptions of various pregnancy related physiological abnormalities were made as early as the 4th century and it was only during the 18th century, that eclampsia was distinguished from epilepsy. Since then (circa. 19th century), classification of eclampsia continued to be refined and the term Pre-eclampsia was introduced in medical textbooks after 1903 [5]. The present classification of PE is based on the report published in the year 2000 by the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy [6].

Manifestation of PE is deemed to be a complex disease process encompassing interplay of genetic, environmental, and immunoregulatory factors [7]. Foremost among a host of factors to beget PE are dysregulated angiogenesis and accentuated maternal systemic Th1 type of inflammatory response. In an effort to comprehend the genetic basis of PE, a recently performed genome-wide analysis suggested TGF β 1 as one of the key candidate genes for PE [8-10].

Further, a growing body of evidence confirms that TGF- β 1, a25KDa homodimeric protein gains prominence in the pathogenesis of PE, by virtue of its pleiotropic nature. TGF- β 1 is believed to control proliferation and differentiation of several cell types including foetal cytotrophoblasts and regulation of trophoblast invasion. It also influences embryonic growth, development as well as apoptosis of

endothelial cells. Fundamentally, this gene is considered as one of the master regulators for monitoring the number of FOXP3+ regulatory T cells [Tregs], which play a crucial role in the maintenance of self-tolerance, physiological immune responses and moreover mediates maternal tolerance to the paternal antigens of the foetus [11-13].

A recent report by Goske et al., with an impressive sample size showed an association of two specified polymorphic variants of TGF β 1 gene with PE and emphasized the importance of carrying out further follow-up studies taking multiple immunoregulatory markers into consideration [14]. Investigations of such nature concurrently might provide insights into the underlying pathophysiology of the disease and novel drug targets.

Polymorphic variants of TGF β 1 gene and serum levels of TGF- β 1 in PE

Genetic polymorphisms in TGF β 1 gene, which is mapped to human chromosome 19 [19q13.1-13.3] [15], have been studied for their association with PE. A couple of SNPs each in the promoter [-800G>A and -509C>T] and in the coding region [+869T>C and +915G>C] of TGF β 1 gene were the widely explored variants for their influence on PE, among various ethnic groups [16-21]. Owing to their location and significance, these gene variants were experimentally demonstrated to impact the circulating levels of TGF- β 1 [22-23]. The latest association study of Goske et al., has reported a significant link between TGF β 1 T-T and C-C haplotype blocks [corresponding to -509C>T and +869T>C polymorphisms] and PE in south Indian women.

Analyses of circulating concentrations of TGF- β 1 have been performed in patients with PE, which however, have engendered inconsistent results perchance due to variation in the sampling methodology and/or gestational age [24-31]. Two current publications dealing with populations of varying ethnicities, point out towards reduced levels of TGF- β 1 in the second trimester of pregnancy and increased levels during the third trimester and post-delivery in PE women, whereas the scenario is reported to be opposite in normal pregnancies [32,33] (Figure 1a).




Figure 1a: Major functions of TGF-β1 signalling in pregnancy.

In the light of the existing literature and based on the functional significance of the SNPs studied, Goske et al., argue that the intermediary levels associated with heterozygous genotype confer a selective advantage and might protect women from PE, though their study did not involve measurement of serum TGF-β1 levels [22,23]. Their hypothesis was based on the premise that, elevated levels of TGF-β1 might predispose the pregnant women to infections in an environment of high prevalence of infectious agents, whereas, reduced levels could cause impaired angiogenesis, therefore, they proposed that both the extremities might have their impact on the pregnancy as well as its outcome. Further, they stated that women who are heterozygous for the two studied polymorphisms have intermediary levels of TGF-β1 which confer a selective advantage over the disease. Nonetheless, they proposed that systematic studies on the circulating and local concentrations of TGF-β1 levels in relation to genotypes may clarify this aspect (Figure 1b).




Figure 1b: Local vs. systematic effects to TGF-β1 in endothelial cell biology and immune response.

Current therapeutic interventions for PE

PE as a malady of foeto-maternal health has been in existence for several centuries and the etiology of the disease is still unexplained. It is only in the late 20th century that a model for the disease pathophysiology has been proposed. However, the treatment even now remains symptomatic [5]. Contemporary treatment modalities vary based on the time of onset of PE and its severity. The only existing cure accessible for late onset PE is to proceed for delivery of the foetus to avoid further complications to either of the lives involved. Early onset PE presents a difficult situation for the health care provider who has to balance the risk of delivery of a premature child with that of the life-threatening obstetric complications of maternal physiology. Milder version of early onset PE would involve recommendation of simple relaxation and bed rest along with certain dietary supplementation. Dealing with severe early onset PE which is accompanied by seizures, is more challenging and usually involves close monitoring of blood pressure accompanied by administration of anti-hypertensive and anti-convulsing medications. These drugs, however, need judicious administration allowing for their possible teratogenicity effect and potential interference with lactation [34].

Therefore, there is an extremely pressing necessity to develop novel alternative remedial modalities for PE. In line with this notion, a recent study suggested an apheresis based treatment for reduction of plasma levels of a placental protein Flt-1, whose elevated levels are detrimental for normal pregnancy [35]. The statement of Goske et al., raises hopes about enhanced treatment options for PE, relative to the present situation of administering drugs with potent side-effects.

TGF-β1 and therapeutics

Thus far, TGF-β1 as clinical therapeutic target has shown promise in a multitude of diseases such as cancers, autoimmune associated inflammatory conditions and cardiovascular disorders. Monoclonal antibodies like GC-1008 and Metelimumab (CAT 192), small molecule inhibitors like Ly550410 and Ly580276 targeted for blocking the activity of TGF-β1 and TGF-β1 kinase respectively, have been evaluated in phase I and phase II clinical trials of various carcinomas [36].

Likewise, systemic administration of exogenous TGF-β1 protein and TGFβ1 based gene augmentation therapy have shown to be fine impending therapeutic targets in animal models of a wide range of autoimmune and chronic inflammatory diseases [37]. In addition, TGF-β1 inhibition and antagonism has been researched upon in combating diverse cardiovascular ailments such as arrhythmias and cardiomyopathies [38].

Additionally, the viability of systemic TGF-β1 administration is challenging, given the pleiotropism of the immunomodulatory molecule. However, extensive investigations on the mode of delivery and dosage, and the possible spin-offs of TGF-β1 therapy in animal models are warranted for realizing the therapeutic potential of TGF-β1 (Figure 2).




Figure 2: Depicting the impact of TGF- β 1 gene polymorphisms on PE. The intermediary levels associated with heterozygous genotypes confer a selective advantage and protect women from PE.

A host of published articles established that, seminal fluid induced immune tolerance towards the foetus by activating Tregs, mainly due to the presence of the cytokine TGF- β 1 [39-41]. The substantial decrease of Tregs in women with PE could most likely be ascribed to the lack of optimal TGF- β 1 [42,43]. Differential TGF- β 1 secretion during diverse stages of pregnancy has been demonstrated to influence optimal angiogenesis and placentation for successful pregnancy outcome [8,44]. Hence, TGF- β 1 shows great promise as a potential therapeutic candidate for PE. Exogenous administration of TGF- β 1 could hold hope of rectifying the optimal concentrations in a scenario of abnormally low levels. Alternatively, in the setting of elevated TGF- β 1 levels, therapeutic intervention could involve employing monoclonal antibodies for blockade of TGF- β 1 signalling. In addition, a further strategy would be to have a cell-based therapeutic procedure by employing Tregs, for achieving immunoregulation in PE.

Future Directions

As mentioned earlier the levels of TGF- β 1 in healthy individuals are maintained in a delicately poised manner not only during pregnancy, but also at various stages of life. Carefully designed studies for elucidation of the fine fluctuations in serum TGF- β 1 concentrations would be of paramount use in equipping us to realise, appreciate and utilize the therapeutic potential of TGF- β 1. Future studies must also take into account the consequences of the dichotomous actions of this pleiotropic cytokine before embarking on therapeutic endeavours.

Furthermore, emerging evidence points towards the potentiality of employing members of the TGF- β superfamily of proteins, soluble endoglin [a co-receptor for TGF- β 1], proangiogenic and antiangiogenic proteins like placental growth factor and soluble fms-like tyrosine kinase 1 (sFlt1) respectively, as prospective diagnostic and therapeutic biomarkers [45-47]. Investigations on these additional biomolecules would facilitate generation of novel attractive therapeutics for PE.

In conclusion, the findings of Goske et al., propose that TGF- β 1, the potent immunoregulatory cytokine, might be considered as one of the possible key players of PE pathogenesis. Their study raises multiple avenues for further research on immunomodulatory molecules and their role in PE. This would pave the way for novel therapeutic modalities in the future.

Acknowledgement

We extend our thanks to University Grants Commission (UGC), New Delhi, India for financial support [F.No.34-217/2008 (SR)]. We acknowledge the scholarship provided to Mrs. Goske Deepthi under the UGC-BSR scheme.

Author Contributions

Parveen Jahan conceived the manuscript, helped with manuscript drafting and gave critical inputs. Goske Deepthi and Kamakshi Chaitrhi Ponnaluri together drafted and shaped the manuscript. Komaravalli Prasanna Latha provided valuable insights for drafting the manuscript.

References

1. Manjusha S, Vandana N, Amit M, Ronak S, Atmaram P (2014) Incidence of pregnancy induced hypertension and prescription pattern of antihypertensive drugs in pregnancy. *Int J Pharm Sci Res* 5: 163-170.
2. Villar J, Say L, Gulmezoglu AM, Meraldi M, Lindheimer MD et al. (2003) Eclampsia and pre-eclampsia: a health problem for 2000 years. In: *Pre-eclampsia*, Critchly H, MacLean A, Poston L, Walker J, (edr) *Preeclampsia and Maternal Mortality: a Global Burden*. RCOG Press, London.
3. Ronsmans C, Graham WJ, Lancet Maternal Survival Series steering group (2006) Maternal mortality: who, when, where, and why. *Lancet* 368: 1189-1200.
4. *Preeclampsia: A Decade of Perspective, Building a Global Call to Action* (2010) Preeclampsia Foundation, Melbourne, Florida 2010.
5. Bell MJ (2010) A historical overview of preeclampsia-eclampsia. *J Obstet Gynecol Neonatal Nurs* 39: 510-518.
6. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program (2000) Report of the national high blood pressure education program working group on high blood pressure in pregnancy. *Am J Obstet Gynecol* 183: S1-S22.
7. Jebbink J, Wolters A, Fernando F, Afink G, van der Post J, et al. (2012) Molecular genetics of preeclampsia and HELLP syndrome - a review. *Biochim Biophys Acta* 1822: 1960-1969.
8. Wang A, Rana S, Karumanchi SA (2009) Preeclampsia: the role of angiogenic factors in its pathogenesis. *Physiology (Bethesda)* 24: 147-158.
9. Redman CW, Sargent IL (2010) Immunology of pre-eclampsia. *Am J Reprod Immunol* 63: 534-543.
10. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y (2007) The role of the immune system in preeclampsia. *Mol Aspects Med* 28: 192-209.
11. Clark DA, Coker R (1998) Transforming growth factor-beta (TGF-beta). *Int J Biochem Cell Biol* 30: 293-298.
12. Simpson H, Robson SC, Bulmer JN, Barber A, Lyall F (2002) Transforming growth factor beta expression in human placenta and placental bed during early pregnancy. *Placenta* 23: 44-58.
13. Li X, Shen L, Tan H (2014) Polymorphisms and plasma level of transforming growth factor-Beta 1 and risk for preeclampsia: a systematic review. *PLoS One* 9: e97230.
14. Deepthi G, Chaitrhi PK, Latha P, Rani VU, Rahman PF, et al. (2015) TGF β 1 Functional Gene Polymorphisms (C-509T and T869C) in the Maternal Susceptibility to Pre-eclampsia in South Indian Women. *Scand J Immunol* 82: 390-397.
15. Fujii D, Brissenden JE, Derynck R, Francke U (1986) Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. *Somat Cell Mol Genet* 12: 281-288.
16. Kim SY, Lim JH, Park SY, Yang JH, Kim MY, et al. (2010) Transforming growth factor-beta 1 gene polymorphisms in Korean patients with preeclampsia. *Am J Reprod Immunol* 63: 291-298.
17. Feizollahzadeh S, Taheripannah R, Khani M, Farokhi B, Amani D (2012) Promoter region polymorphisms in the transforming growth factor

- beta-1 (TGFbeta1) gene and serum TGFbeta1 concentration in preeclamptic and control Iranian women. *J Reprod Immunol* 94: 216-221.
18. Aguilar-Duran M, Salvador-Moysen J, Galaviz-Hernandez C, Vazquez-Alaniz F, Sandoval-Carrillo AA, et al (2014) Haplotype analysis of TGF-beta1 gene in a preeclamptic population of northern Mexico. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health* 4: 14-18.
 19. Stanczuk GA, McCoy MJ, Hutchinson IV, Sibanda EN (2007) The genetic predisposition to produce high levels of TGF-beta1 impacts on the severity of eclampsia/pre-eclampsia. *Acta Obstet Gynecol Scand* 86: 903-908.
 20. de Lima TH, Sass N, Mattar R, Moron AF, Torloni MR, et al. (2009) Cytokine gene polymorphisms in preeclampsia and eclampsia. *Hypertens Res* 32: 565-569.
 21. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, et al. (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. *Hum Mol Genet* 8: 93-97.
 22. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, et al. (2003) Transforming Growth Factor1 Signal Peptide Variant Increases Secretion in Vitro and is associated with increased incidence of Invasive Breast Cancer. *Cancer Res* 63: 2610-2615.
 23. Syrris P, Carter ND, Metcalfe JC, Kemp PR, Grainger DJ, et al. (1998) Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. *Clin Sci (Lond)* 95: 659-667.
 24. Huber A, Hefler L, Tempfer C, Zeisler H, Lebrecht A, et al. (2002) Transforming growth factor-beta 1 serum levels in pregnancy and preeclampsia. *Acta Obstet Gynecol Scand* 81: 168-171.
 25. Muy-Rivera M, Sanchez SE, Vadachkoria S, Qiu C, Bazul V, et al. (2004) Transforming growth factor-beta1 (TGF-beta1) in plasma is associated with preeclampsia risk in Peruvian women with systemic inflammation. *Am J Hypertens* 17: 334-338.
 26. Lim JH, Kim SY, Park SY, Lee MH, Yang JH, et al. (2009) Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia. *Prenat Diagn* 29: 471-476.
 27. Peraçoli MT, Menegon FT, Borges VT, de Araújo Costa RA, Thomazini-Santos IA, et al. (2008) Platelet aggregation and TGF-beta(1) plasma levels in pregnant women with preeclampsia. *J Reprod Immunol* 79: 79-84.
 28. Djurovic S, Schjetlein R, Wisløff F, Haugen G, Husby H, et al. (1997) Plasma concentrations of Lp(a) lipoprotein and TGF-beta1 are altered in preeclampsia. *Clin Genet* 52: 371-376.
 29. Enquobahrie DA, Williams MA, Qiu C, Woelk GB, Mahomed K (2005) Maternal plasma transforming growth factor-beta1 concentrations in preeclamptic and normotensive pregnant Zimbabwean women. *J Matern Fetal Neonatal Med* 17: 343-348.
 30. Madazli R, Aydin S, Uludag S, Vildan O, Tolun N (2003) Maternal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels. *Acta Obstet Gynecol Scand* 82: 797-802.
 31. Szarka A, Rigo J, Lazar L, Beko G, Molvarec A (2010) Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. *BMC immunology* 11: 59.
 32. Singh M, Orazulike NC, Ashmore J, Konje JC (2013) Changes in maternal serum transforming growth factor beta-1 during pregnancy: a cross-sectional study. *Biomed Res Int* 2013: 318464.
 33. Li X, Shen L, Tan H (2014) Polymorphisms and plasma level of transforming growth factor-Beta 1 and risk for preeclampsia: a systematic review. *PLoS One* 9: e97230.
 34. McCoy S, Baldwin K (2009) Pharmacotherapeutic options for the treatment of preeclampsia. *Am J Health Syst Pharm* 66: 337-344.
 35. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, et al. (2011) Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. *Circulation* 124: 940-950.
 36. Wrzesinski SH, Wan YY, Flavell RA (2007) Transforming growth factor-beta and the immune response: implications for anticancer therapy. *Clin Cancer Res* 13: 5262-5270.
 37. Chen W, Wahl SM (1999) Manipulation of TGF-beta to control autoimmune and chronic inflammatory diseases. *Microbes Infect* 1: 1367-1380.
 38. Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. *Immunology* 118: 10-24.
 39. Robertson SA, Bromfield JJ, Tremellen KP (2003) Seminal 'priming' for protection from pre-eclampsia—a unifying hypothesis. *J Reprod Immunol* 59: 253-265.
 40. Robertson SA, Ingman WV, O'Leary S, Sharkey DJ, Tremellen KP (2002) Transforming growth factor beta--a mediator of immune deviation in seminal plasma. *J Reprod Immunol* 57: 109-128.
 41. Robertson SA, Guerin LR, Moldenhauer LM, Hayball JD (2009) Activating T regulatory cells for tolerance in early pregnancy - the contribution of seminal fluid. *J Reprod Immunol* 83: 109-116.
 42. Toldi G, Svec P, Vászrhelyi B, Mészáros G, Rigó J, et al. (2008) Decreased number of FoxP3+ regulatory T cells in preeclampsia. *Acta Obstet Gynecol Scand* 87: 1229-1233.
 43. Hafeez NA, Fouda Mel-T, Abdel Gawad ER, Assar T, Mansour AI (2014) The role of regulatory T cells in preeclampsia. *Egypt J Immunol* 21: 45-55.
 44. Singh M, Orazulike NC, Ashmore J, Konje JC (2013) Changes in maternal serum transforming growth factor beta-1 during pregnancy: a cross-sectional study. *Biomed Res Int* 2013: 318464.
 45. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, et al. (2006). Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. *N Engl J Med* 355: 992-1005.
 46. Shaarawy M, El Meleigy M, Rasheed K (2001) Maternal serum transforming growth factor beta-2 in preeclampsia and eclampsia, a potential biomarker for the assessment of disease severity and fetal outcome. *J Soc Gynecol Investig* 8: 27-31.
 47. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. *Nat Med* 12: 642-649.